Media Inquiries

Media entities seeking information about Zydus Therapeutics, Inc. can contact us and a representative will respond within 2 business days.

Sort By:


Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC

December 10, 2021

Full Story

Zydus granted Fast Track Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC)

December 9, 2020

Full Story